LoginSignup
image de profil
thewolfofgetquin
@thewolfofgetquin
5H·

Floor at Novo

19
22 Commentaires
image de profil
Shem_sen@Shem_sen
5H
I hope soooo🙈
•
8
•
image de profil
thewolfofgetquin@thewolfofgetquin
5H
@Shem_sen we have a double bottom. and strong support now the momentum must come
•
1
•
image de profil
Sansebastian@Sansebastian
5H
Technically not yet 😉
•
1
•
Chiefwiggum@Hidalidsch
2H
@Sansebastian when would this technically be reached? ✌🏽
••
image de profil
Sansebastian@Sansebastian
2H
@Hidalidsch the short-term bottom is confirmed above 470 Danish kroner. From there, a new upward trend "could" start
•
1
•
market_expert_gbtws@market_expert_gbtws
4H
Inverse shoulder-head-shoulder formation is emerging. That looks good. 🙃
••
image de profil
D.S.@Cato_Bamboo
4H
We'll take another look tomorrow...........🤔
••
image de profil
Ph1l1pp@Ph1l1pp
4H
1 year view -50% "the bottom is in"
••
image de profil
thewolfofgetquin@thewolfofgetquin
4H
@Ph1l1pp oh philipp we have discussed bitcoin before and now look at where we are my dear 😉
••
image de profil
Sansebastian@Sansebastian
4H
@Ph1l1pp What does the floor have to do with the 1-year view?
••
image de profil
Ph1l1pp@Ph1l1pp
4H
@Sansebastian Who calls the bottom after a 50% correction? As long as the company has anything to offer fundamentally, a bottom should have already been formed 😅
••
image de profil
thewolfofgetquin@thewolfofgetquin
4H
@Ph1l1pp Nvidia also corrected 50% and we now had a bottom?🤣
••
image de profil
Ph1l1pp@Ph1l1pp
4H
@thewolfofgetquin Unfortunately I can't remember the discussion, but I hope you bought the floor too ;)
••
image de profil
Sansebastian@Sansebastian
4H
@Ph1l1pp It has been going up for years, so a 50% correction is perfectly okay.
This has nothing to do with the fundamental data of the company
•
3
•
image de profil
Ph1l1pp@Ph1l1pp
4H
@Sansebastian Clear, fundamental data and macroeconomic environment
••
paul@paulhoh
4H
So would you recommend buying it?
••
image de profil
thewolfofgetquin@thewolfofgetquin
4H
@paulhoh perfect entry was actually this morning and at noon. but first tranches could be made now and then buy order again at 64€
••
image de profil
Joker@Blizzard
3H
Current share price and technical indicators
The current price of NOVO-B.CO is EUR 60.26 (as of 2025-05-12 20:39:40)[1].

Indicator Value Date
Price 60.26 EUR 2025-05-12
R1 61.23 -
S1 59.29 -
Detailed technical analysis
Trend analysis:

The long-term trend shows a clear downward movement since the beginning of 2023.
The price is below important moving averages (e.g. 50-week moving average at around EUR 75).
No support and resistance:

Short-term support levels: EUR 59.29 (S1), EUR 58.13 (S2), EUR 56.37 (S3)
Resistance levels: EUR 61.23 (R1), EUR 62.19 (R2), EUR 63.15 (R3)
Volatility:

The historical volatility shows an increased fluctuation range in recent months.
The ATR (Average True Range) is around EUR 2.50.
Momentum indicators:

RSI (14): Currently at 45.12, indicating a neutral position.
MACD: The MACD is below the signal line, indicating a bearish trend.
Entry points
Based on the technical indicators, the following points in time could be interesting for an entry:

Short-term entry opportunity:

If the price holds the support level at EUR 59.29 (S1) and rises again.
If the RSI value is below 30 (oversold condition).
Medium-term entry opportunity:

If the resistance level at EUR 61.23 (R1) is broken with rising volume.
If the MACD crosses the signal line from below.
Future prospects and market influencing factors
Pharmaceutical sector trends:

Novo Nordisk has lowered its 2025 sales growth forecast to 13-21% (at constant exchange rates), from 16-24% previously[2].
The GLP-1 receptor agonist market remains highly competitive, particularly with the emergence of compounded products.
Regulatory developments:

The approval and availability of generic or biosimilar products could impact the market.
Market sentiment:

Despite the downgrade of the forecast, the share price rose in the pre-market, indicating a degree of confidence.
Risks and opportunities
Risks: Further slowdown in demand for GLP-1 receptor agonists, regulatory challenges.
Opportunities: Positive developments in the pipeline, strategic partnerships (e.g. with Hims & Hers).
Conclusion
The technical analysis points to a cautious entry at support levels. Future prospects are uncertain due to market and regulatory dynamics. Continuous monitoring of technical indicators and market developments is advisable.
••
paul@paulhoh
2H
@Blizzard Hey, thanks a lot. Where did you get this analysis? Thanks in advance.
•
1
•
image de profil
Joker@Blizzard
1H
@paulhoh Because it is in my portfolio and I analyze all of mine every 2 months or update and with 60 pieces. You can do something like that quickly. If you need anything else, I still have some free time 🤣
•
1
•
image de profil
Mark777@Mark777
1H
@Seebi Your voice is still missing😘😅
••
image de profil
C_Montgomery_Burns@C_Montgomery_Burns
1H
Mmh, then I'll probably get another small tranche tomorrow. 🤔
••
Participez à la conversation
S'inscrireConnexion